Physician profile
Judith Newell
NPI 1134140064
$3,490.30
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,788 · 2021: $702.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $2,812.13 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.50 | 2021 | |
| Glaxosmithkline, LLC. | $133.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $127.05 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $46.49 | 2021 | |
| Advanced Respiratory, INC | $33.71 | 2021 | |
| Csl Behring | $28.68 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.27 | 2021 | |
| Grifols USA, LLC | $26.50 | 2021 | |
| Mylan Specialty L.P. | $22.90 | 2021 | |
| Genzyme Corporation | $22.22 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.24 | 2021 | |
| Insmed, INC. | $15.56 | 2021 | |
| United Therapeutics Corporation | $14.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.05 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Newell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.